No, Viagra (sildenafil) is NOT contraindicated with Xarelto (rivaroxaban)
There is no formal contraindication to using sildenafil with rivaroxaban, but caution is warranted due to potential drug interactions that may increase rivaroxaban levels and bleeding risk.
Key Interaction Mechanism
Sildenafil is a PDE5 inhibitor that acts as a P-glycoprotein (P-gp) inhibitor. Since rivaroxaban is a substrate of both CYP3A4 and P-gp, concomitant use with P-gp inhibitors can increase rivaroxaban plasma concentrations 1.
Evidence from In Vitro Studies
Research demonstrates that PDE5 inhibitors significantly inhibit rivaroxaban efflux:
- Sildenafil inhibited rivaroxaban efflux by 99% at 100 µM concentrations
- The IC50 for sildenafil was 8 µM for rivaroxaban
- This represents strong in vitro inhibition of DOAC efflux by PDE5 inhibitors 2
However, these are in vitro findings, and clinical significance remains uncertain as the study authors explicitly noted that "in vivo studies are required to determine the clinical relevance of these interactions" 2.
Clinical Guidance
FDA Labeling Considerations
The Viagra FDA label does not list rivaroxaban as a contraindication. The only absolute contraindications for sildenafil are:
- Nitrates or nitric oxide donors (due to severe hypotension risk)
- Known hypersensitivity to sildenafil 3
The label does note that potent CYP3A4 inhibitors increase sildenafil levels, but sildenafil itself is not classified as a strong CYP3A4/P-gp inhibitor in the rivaroxaban interaction profile 3.
Rivaroxaban Interaction Profile
According to current guidelines, rivaroxaban should be avoided with combined strong CYP3A4 and P-gp inhibitors (such as ketoconazole, ritonavir, cobicistat) due to increased bleeding risk 1.
Sildenafil does not fall into this "strong inhibitor" category, though it does have P-gp inhibitory effects 2.
Practical Recommendations
Safe Co-Administration Strategy
Use standard dosing of both medications in patients with normal renal function
Monitor for bleeding signs more carefully than usual, particularly:
- Unexplained bruising
- Prolonged bleeding from minor cuts
- Blood in urine or stool
- Unusual fatigue (possible internal bleeding)
Exercise greater caution in high-risk scenarios:
- Renal impairment (CrCl < 50 mL/min) - P-gp inhibition has greater effect with reduced kidney function 1
- Elderly patients (>65 years)
- Patients on other medications that affect CYP3A4 or P-gp
- Lower body weight patients
Consider rivaroxaban dose adjustment only if multiple risk factors are present (advanced age + renal impairment + sildenafil use)
Common Pitfall to Avoid
Do not confuse this interaction with the absolute contraindication between sildenafil and nitrates. The rivaroxaban-sildenafil interaction is a potential pharmacokinetic concern requiring monitoring, not an absolute contraindication like the sildenafil-nitrate combination 3.
The combination can be used safely in most patients with appropriate clinical vigilance for bleeding complications.